Abstract
In pulmonary hypertension (PH), thrombosis and thromboembolism may occur as primary events associated with inherited or acquired thrombophilia. Alternatively, in situ thrombosis may develop as a complication of pre-existing vasculopathy as in the case of idiopathic PH and related disorders (so called pulmonary arterial hypertension). In these disorders, a number of abnormalities has been described involving endothelial cells, platelets and other circulating cellular and soluble elements. These abnormalities are suggestive of a shift of pulmonary vascular microenvironment toward a procoagulant, prothrombotic and antifibrinolytic pattern. The abnormalities described so far include circulating antiphospholipid antibodies, increased plasma levels of platelet aggregating agents (serotonin, thromboxane), adhesion molecules (P-selectin, von Willebrand factor), antifibrinolytic enzymes (plasminogen activator inhibitor 1) and cytokines. Also, decreased endothelial production of natural anticoagulants (thrombomodulin) and platelet antiaggregating substances (nitric oxide, prostacyclin) have been demonstrated. The present review is focused on the procoagulant, prothrombotic and antifibrinolytic mechanisms so far identified in PH, in both clinical setting and animal models. Understanding of these mechanisms is crucial for a proper selection of anticoagulant and antithrombotic therapies and provides the rationale for development of novel therapeutic options.
Keywords: Pulmonary hypertension, endothelial dysfunction, thrombosis, platelets, anticoagulant therapy, antiplatelet drugs, thrombophilia, hypoxia
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Volume: 4 Issue: 1
Author(s): Antonio A. Lopes
Affiliation:
Keywords: Pulmonary hypertension, endothelial dysfunction, thrombosis, platelets, anticoagulant therapy, antiplatelet drugs, thrombophilia, hypoxia
Abstract: In pulmonary hypertension (PH), thrombosis and thromboembolism may occur as primary events associated with inherited or acquired thrombophilia. Alternatively, in situ thrombosis may develop as a complication of pre-existing vasculopathy as in the case of idiopathic PH and related disorders (so called pulmonary arterial hypertension). In these disorders, a number of abnormalities has been described involving endothelial cells, platelets and other circulating cellular and soluble elements. These abnormalities are suggestive of a shift of pulmonary vascular microenvironment toward a procoagulant, prothrombotic and antifibrinolytic pattern. The abnormalities described so far include circulating antiphospholipid antibodies, increased plasma levels of platelet aggregating agents (serotonin, thromboxane), adhesion molecules (P-selectin, von Willebrand factor), antifibrinolytic enzymes (plasminogen activator inhibitor 1) and cytokines. Also, decreased endothelial production of natural anticoagulants (thrombomodulin) and platelet antiaggregating substances (nitric oxide, prostacyclin) have been demonstrated. The present review is focused on the procoagulant, prothrombotic and antifibrinolytic mechanisms so far identified in PH, in both clinical setting and animal models. Understanding of these mechanisms is crucial for a proper selection of anticoagulant and antithrombotic therapies and provides the rationale for development of novel therapeutic options.
Export Options
About this article
Cite this article as:
Lopes A. Antonio, Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (1) . https://dx.doi.org/10.2174/187152506775268794
DOI https://dx.doi.org/10.2174/187152506775268794 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress in Signal Transduction Research of the Angiotensin II Type-1 Receptor: Protein Kinases, Vascular Dysfunction and Structural Requirement
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Use of Novel Oral Anticoagulants in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Treatment of Atopic Dermatitis: Current Status and Future Prospects
Current Drug Therapy Forward and Backward Aortic Components and Reflection Indexes in Children and Adolescents: Determinants and Role in High Pressure States
Current Hypertension Reviews Withdrawal Notice: Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease
Current Drug Targets Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Preeclampsia as a Multifactorial Pregnancy Disorder: Clinical Symptoms,Diagnostic Tools and Research Strategies
Current Women`s Health Reviews Matrix Metalloproteinases in Lung Diseases
Current Protein & Peptide Science Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Editorial [Hot Topic: Recent Progress in the Development of Anti-Diabetic Drugs (Guest Editor: J. Eckel)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery Fish Gelatin Hydrolysates as Antioxidant, Antihypertensive, and Antidiabetic: The Plausible Mechanisms
Mini-Reviews in Organic Chemistry Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Combating Obesity by Targeting Nuclear Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture
Current Drug Safety Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
Current Cancer Drug Targets